Board Change • Jan 16
Less than half of directors are independent No new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 4 experienced directors. No highly experienced directors. 1 independent director (3 non-independent directors). Internal Director Choon-Jae Park was the last director to join the board, commencing their role in 2018. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Insufficient board refreshment. Duyuru • Mar 18
Wellbiotec Co., Ltd., Annual General Meeting, Mar 31, 2025 Wellbiotec Co., Ltd., Annual General Meeting, Mar 31, 2025, at 09:00 Tokyo Standard Time. Location: conference room, 17, yeongdong-daero 106-gil, gangnam-gu, seoul South Korea Reported Earnings • Apr 10
Full year 2023 earnings released: ₩820 loss per share (vs ₩325 loss in FY 2022) Full year 2023 results: ₩820 loss per share (further deteriorated from ₩325 loss in FY 2022). Revenue: ₩72.1b (down 54% from FY 2022). Net loss: ₩64.9b (loss widened 211% from FY 2022). Over the last 3 years on average, earnings per share has increased by 32% per year but the company’s share price has fallen by 48% per year, which means it is significantly lagging earnings. New Risk • Apr 05
New major risk - Revenue and earnings growth Earnings have declined by 13% per year over the past 5 years. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If profits are declining over an extended period, then in most cases the share price will decline over time unless the company can turn around its fortunes. A trend of falling earnings can be very difficult to turn around. If the company is well already established it may also be a sign the company has matured and is in decline. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (14% average weekly change). Earnings have declined by 13% per year over the past 5 years. Minor Risks Shareholders have been diluted in the past year (37% increase in shares outstanding). Market cap is less than US$100m (₩53.2b market cap, or US$39.4m). New Risk • Nov 01
New minor risk - Market cap size The company's market capitalization is less than US$100m. Market cap: ₩134.6b (US$99.1m) This is considered a minor risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (13% average weekly change). Earnings have declined by 0.8% per year over the past 5 years. Minor Risks Shareholders have been diluted in the past year (37% increase in shares outstanding). Market cap is less than US$100m (₩134.6b market cap, or US$99.1m). Duyuru • Jun 14
Wellbiotec Co., Ltd. announced that it has received KRW 8.00000001 billion in funding from K-Impact Fund On June 13, 2023, Wellbiotec Co., Ltd. closed the transaction. Reported Earnings • May 18
First quarter 2023 earnings released: ₩8.00 loss per share (vs ₩63.00 profit in 1Q 2022) First quarter 2023 results: ₩8.00 loss per share (down from ₩63.00 profit in 1Q 2022). Revenue: ₩26.5b (down 57% from 1Q 2022). Net loss: ₩520.6m (down 114% from profit in 1Q 2022). Over the last 3 years on average, earnings per share has increased by 47% per year but the company’s share price has fallen by 16% per year, which means it is significantly lagging earnings. Reported Earnings • Mar 26
Full year 2022 earnings released: ₩98.00 loss per share (vs ₩383 loss in FY 2021) Full year 2022 results: ₩98.00 loss per share (improved from ₩383 loss in FY 2021). Revenue: ₩190.9b (up 57% from FY 2021). Net loss: ₩6.28b (loss narrowed 70% from FY 2021). Over the last 3 years on average, earnings per share has increased by 26% per year but the company’s share price has fallen by 15% per year, which means it is significantly lagging earnings. Duyuru • Feb 08
Wellbiotec Co., Ltd. announced that it expects to receive KRW 10 billion in funding from Sangsangin Plus Savings Bank Co.,Ltd., Sangsangin Savings Bank, Investment Arm Wellbiotec Co., Ltd. announced a private placement of series 32 Unsecured privately placed convertible bonds with bearer interest for the gross proceeds of KRW 10,000,000,000 on February 7, 2023. The transaction will include participation from retuning investor Sangsangin Savings Bank, Investment Arm and Sangsangin Plus Savings Bank Co.,Ltd. for KRW 5,000,000,000 each. The bonds are 100% convertible into 8,841,732 shares at a fixed conversion price of KRW 1,131 per share from February 9, 2024 to January 09, 2026. The bonds bear 3% interest rate and 8% yield to maturity and will mature on February 9, 2026. The transaction has been approved by the board of directors and is expected to close on February 9, 2023. The bonds are restricted to a hold period of one year from the date of issuance. Board Change • Nov 16
Less than half of directors are independent No new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 4 experienced directors. No highly experienced directors. 1 independent director (3 non-independent directors). Internal Director Choon-Jae Park was the last director to join the board, commencing their role in 2018. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Insufficient board refreshment. Duyuru • Jun 22
Wellbiotec Co., Ltd. announced that it expects to receive KRW 3 billion in funding from KH Feelux Co., Ltd. Wellbiotec Co., Ltd. announced a private placement of 31st series no-guaranteed Private convertible bonds with barer type interest part convertible bonds for gross proceeds of KRW 3,000,000,000 on June 21, 2022. The transaction included participation from new investor KH Feelux Co., Ltd. The bonds are having coupon rate 5% and will mature on June 22, 2025. The bonds will be 100% convertible into 1,951,854 common shares of the company at a fixed conversion price of KRW 1,537 per share from June 22, 2023 to May 25, 2025. The board of directors of the company approved the transaction. The subscription and payment date are June 22, 2022. Reported Earnings • May 18
First quarter 2022 earnings released: EPS: ₩63.00 (vs ₩44.00 loss in 1Q 2021) First quarter 2022 results: EPS: ₩63.00 (up from ₩44.00 loss in 1Q 2021). Revenue: ₩62.1b (up 262% from 1Q 2021). Net income: ₩3.68b (up ₩5.76b from 1Q 2021). Profit margin: 5.9% (up from net loss in 1Q 2021). Over the last 3 years on average, earnings per share has fallen by 17% per year whereas the company’s share price has fallen by 14% per year. Board Change • Apr 27
Less than half of directors are independent No new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 4 experienced directors. No highly experienced directors. 1 independent director (3 non-independent directors). Internal Director Choon-Jae Park was the last director to join the board, commencing their role in 2018. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Insufficient board refreshment. Duyuru • Apr 16
Wellbiotec Co., Ltd. announced that it expects to receive KRW 10 billion in funding from Wise Pacific Holdings Limited Wellbiotec Co., Ltd. (KOSE:A010600) announced a private placement of round 29th and 30th non-guaranteed private equity convertible bonds with bearer interest for gross proceeds of KRW 10,000,000,000 on April 14, 2021. The transaction will include participation from Rover Holdings Co., Ltd. and returning investor Wise Pacific Holdings Limited for KRW 5,000,000,000 each. The bond is issued at maturity interest rate of 4% and surface interest rate of 0%. The 29th bond will mature on May 14, 2024 and 30th bond will mature on June 14, 2024. The bonds will be 100% convertible into 2,833,662 common shares at a fixed conversion price of KRW 3,529 per share. The 29th bonds will convert from May 14, 2022 to April 14, 2024 and 30th bonds will convert from June 14, 2022 to May 14, 2024. The board of directors of the company approved the transaction. The payment date for 29th bonds is May 14, 2021 and 30th bonds is June 14, 2021.The bonds issued in the transaction will have a hold period of one year from the date of issuance. Duyuru • Mar 11
Wellbiotec Co., Ltd., Annual General Meeting, Mar 30, 2021 Wellbiotec Co., Ltd., Annual General Meeting, Mar 30, 2021, at 09:00 Korea Standard Time. Is New 90 Day High Low • Feb 26
New 90-day high: ₩2,955 The company is up 28% from its price of ₩2,300 on 27 November 2020. The South Korean market is up 16% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Luxury industry, which is up 20% over the same period. Is New 90 Day High Low • Jan 22
New 90-day high: ₩2,780 The company is up 29% from its price of ₩2,155 on 23 October 2020. The South Korean market is up 32% over the last 90 days, indicating the company underperformed over that time. However, it outperformed the Luxury industry, which is up 11% over the same period. Is New 90 Day High Low • Jan 05
New 90-day high: ₩2,660 The company is up 17% from its price of ₩2,275 on 07 October 2020. The South Korean market is up 23% over the last 90 days, indicating the company underperformed over that time. However, it outperformed the Luxury industry, which is up 8.0% over the same period. Is New 90 Day High Low • Dec 15
New 90-day high: ₩2,550 The company is up 3.0% from its price of ₩2,470 on 16 September 2020. The South Korean market is up 12% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Luxury industry, which is up 5.0% over the same period. Is New 90 Day High Low • Oct 26
New 90-day low: ₩2,060 The company is down 41% from its price of ₩3,480 on 28 July 2020. The South Korean market is up 6.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Luxury industry, which is up 14% over the same period. Is New 90 Day High Low • Oct 08
New 90-day low: ₩2,215 The company is down 23% from its price of ₩2,875 on 10 July 2020. The South Korean market is up 11% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Luxury industry, which is up 6.0% over the same period. Duyuru • Aug 27
Wellbiotec Co., Ltd. (KOSE:A010600) agreed to acquire Kumyoungeng Co., Ltd from Seungho Choi for KRW 35 billion. Wellbiotec Co., Ltd. (KOSE:A010600) agreed to acquire Kumyoungeng Co., Ltd from Seungho Choi for KRW 35 billion on August 25, 2020. Wellbiotec Co., Ltd. will acquire 0.05 million shares of Kumyoungeng Co., Ltd. Wellbiotec Co., Ltd. shall pay KRW 2.5 billion as down payment on the contract date, KRW 17.5 billion on October 7, 2020 and balance of KRW 15 billion on November 6, 2020. For the period ending December 2019, Kumyoungeng Co., Ltd reported total assets of KRW 27.75 billion, total equity of KRW 15.86 billion, sales of KRW 50.29 billion and net income of KRW 3.72 billion. The transaction is expected to complete on November 6, 2020. 